Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Wavelength-Pharmaceuticals-Insert
    X

    Find Clinical Drug Pipeline Developments & Deals by Tiziana Life Sciences

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Therapeutic Area filter
      Study Phase filter
        Country filter
          News Type filter
            Company filter
              refresh

              Companies By Therapeutic Area Full Screen

              Development Status Full Screen

              Tiziana Life Sciences

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody

              Contact the Supplier

              Lead Product(s): Foralumab,CAR-T Therapy

              Therapeutic Area: Oncology Product Name: TZLS-401

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 16, 2020

              Details:

              Tiziana has submitted a patent application on potential use of Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), to improve success of CAR-T therapy for cancer and other human diseases.

              Tiziana Life Sciences

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Tiziana Life Sciences Announces Agreement STC Biologics for GMP Manufacturing

              Contact the Supplier

              Lead Product(s): TZLS-501

              Therapeutic Area: Infections and Infectious Diseases Product Name: TZLS-501

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: STC Biologics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement June 29, 2020

              Details:

              Tiziana's proprietary inhalation technology for direct delivery of mAbs or other small molecule drugs such as Remdesivir® (Roche) to lungs could potentially be a transformational therapy for developing a rapid treatment for COVID-19

              Tiziana Life Sciences

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Tiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D from Rasna Therapeutics

              Contact the Supplier

              Lead Product(s): Dactinomycin

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Recipient: Rasna Therapeutics

              Deal Size: $0.6 million Upfront Cash: $0.1 million

              Deal Type: Acquisition April 24, 2020

              Details:

              Actinomycin-D from Rasna Therapeutics will expand Tiziana Life Sciences's pipeline. The drug is on the WHO's List of Essential Medicines as the most effective medicines needed in a health system.

              Tiziana Life Sciences

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Tiziana Lifesciences Develops Novel Investigational Treatment For Patients Infected with COVID-19

              Contact the Supplier

              Lead Product(s): TZLS-501

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 09, 2020

              Details:

              Development of this technology is a step forward toward expediting development of TZLS-501, for treatment of patients infected with COVID-19 (SARS-CoV-2) coronavirus.

              Tiziana Life Sciences

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $10 Million

              Contact the Supplier

              Lead Product(s): TZLS-501

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: ThinkEquity

              Deal Size: $10.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering March 12, 2020

              Details:

              Net proceeds to be used to advance the clinical development of Foralumab for Crohn’s Disease and M.S (ii) to expedite clinical development of TZLS-501 for coronavirus COVID-19.

              Tiziana Life Sciences

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Tiziana Life Sciences Developing TZLS-501 as Treatment for Coronavirus Patients

              Contact the Supplier

              Lead Product(s): TZLS-501

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 11, 2020

              Details:

              Tiziana plans to administer TZLS-501 using a proprietary formulation technology. Tests have already shown that the treatment rapidly depletes circulating levels of IL-6 in the blood.

              Tiziana Life Sciences

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Tiziana Reports Phase 1 Clinical Data Demonstrating Oral Treatment with Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, is Well-toler...

              Contact the Supplier

              Lead Product(s): Foralumab

              Therapeutic Area: Healthy Volunteers Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 09, 2020

              Details:

              Foralumab encapsulated in an enteric-coated capsule, was well-tolerated at all doses tested and there were no drug-related safety issues even at the highest dose of 5 mg in this trial.

              PharmaCompass__DigitalAd